These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 18462814)

  • 41. The prevalence of transmitted antiretroviral drug resistance in treatment-naïve patients and factors influencing first-line treatment regimen selection.
    Huang HY; Daar ES; Sax PE; Young B; Cook P; Benson P; Cohen C; Scribner A; Hu H
    HIV Med; 2008 May; 9(5):285-93. PubMed ID: 18400075
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Prevalence of antiretroviral drug genotypic resistance among HIV patients in Cuenca, Spain].
    Rodriguez-Escudero MJ; Prada de Medio E; Rosa Herranz C; Martinez Medina MC; Franquelo Gutierrez R
    Rev Esp Quimioter; 2007 Jun; 20(2):203-5. PubMed ID: 17893756
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.
    Calza L; Manfredi R; Pocaterra D; Chiodo F
    Int J STD AIDS; 2008 Aug; 19(8):541-4. PubMed ID: 18663041
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
    McColl DJ; Chappey C; Parkin NT; Miller MD
    Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical utility of genotyping resistance test on determining the mutation patterns in HIV-1 CRF01_AE and subtype B patients receiving antiretroviral therapy in Hong Kong.
    Yam WC; Chen JH; Wong KH; Chan K; Cheng VC; Lam HY; Lee SS; Zheng BJ; Yuen KY
    J Clin Virol; 2006 Apr; 35(4):454-7. PubMed ID: 16386461
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
    Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
    J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV-1 drug resistance-associated mutations among antiretroviral-naive Thai patients with chronic HIV-1 infection.
    Manosuthi W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    J Med Virol; 2013 Feb; 85(2):194-9. PubMed ID: 23161095
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

  • 50. Understanding transmitted HIV resistance through the experience in the USA.
    Taiwo B
    Int J Infect Dis; 2009 Sep; 13(5):552-9. PubMed ID: 19136289
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.
    Garcia-Perez J; Sanchez-Palomino S; Perez-Olmeda M; Fernandez B; Alcami J
    J Med Virol; 2007 Feb; 79(2):127-37. PubMed ID: 17177310
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-HIV drugs.
    De Clercq E
    Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes.
    SPREAD programme
    AIDS; 2008 Mar; 22(5):625-35. PubMed ID: 18317004
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Performance and quality assurance of genotypic drug-resistance testing for human immunodeficiency virus type 1 in Japan.
    Fujisaki S; Fujisaki S; Ibe S; Asagi T; Itoh T; Yoshida S; Koike T; Oie M; Konda M; Sadamasu K; Nagashima M; Gatanaga H; Matsuda M; Ueda M; Masakane A; Hata M; Mizogami Y; Mori H; Minami R; Okada K; Watanabe K; Shirasaka T; Oka S; Sugiura W; Kaneda T
    Jpn J Infect Dis; 2007 May; 60(2-3):113-7. PubMed ID: 17515643
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes.
    Holguín A; Ramirez de Arellano E; Rivas P; Soriano V
    AIDS Rev; 2006; 8(2):98-107. PubMed ID: 16848277
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines.
    de Mendoza C; Anta L; García F; Pérez-Elías MJ; Gutiérrez F; Llibre JM; Menéndez-Arias L; Dalmau D; Soriano V
    AIDS Rev; 2009; 11(1):39-51. PubMed ID: 19290033
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HIV-1 drug resistance in Thailand: before and after National Access to Antiretroviral Program.
    Sutthent R; Arworn D; Kaoriangudom S; Chokphaibulkit K; Chaisilwatana P; Wirachsilp P; Thiamchai V; Sirapraphasiri T; Tanprasertsuk S
    J Clin Virol; 2005 Dec; 34(4):272-6. PubMed ID: 16286051
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system.
    Ziermann R; Celis L; Derdelinckx I; Lambert C; Veeck J; Rizzo MG; Vanderborght B; Zissis G; Clumeck N; Fransen K; Vaira D; Hendricks D; Van Laethem K; Vandamme AM; Schmit JC; Knechten H; De Luca A; Louwagie J; Segers P; De Boeck K; Pottel H; De Brauwer A; Hulstaert F
    J Clin Virol; 2004 Dec; 31 Suppl 1():S7-15. PubMed ID: 15567089
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors.
    Bracciale L; Colafigli M; Zazzi M; Corsi P; Meraviglia P; Micheli V; Maserati R; Gianotti N; Penco G; Setti M; Di Giambenedetto S; Butini L; Vivarelli A; Trezzi M; De Luca A
    J Antimicrob Chemother; 2009 Sep; 64(3):607-15. PubMed ID: 19608581
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.
    Fox ZV; Geretti AM; Kjaer J; Dragsted UB; Phillips AN; Gerstoft J; Staszewski S; Clotet B; von Wyl V; Lundgren JD
    AIDS; 2007 Oct; 21(15):2033-42. PubMed ID: 17885293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.